HCW Biologics to Participate in the 2025 Maxim Growth Summit
MWN-AI** Summary
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company based in the U.S., is set to participate in the 2025 Maxim Growth Summit scheduled for October 22-23 at The Hard Rock Hotel in New York City. This event draws together industry leaders and innovators to discuss advancements across various sectors, particularly in biotechnology. Dr. Hing C. Wong, the company’s Founder and CEO, will engage in one-on-one meetings with institutional investors and senior analysts from Maxim during the summit.
Keynote speakers at the event include notable figures such as Larry Kudlow and Christopher Ruddy, while roundtable discussions will feature CEOs from small and mid-cap companies, moderated by Maxim research analysts. The discussions will encompass a broad spectrum of topics, including biotechnology, stem cell therapy, and artificial intelligence, among others.
HCW Biologics specializes in developing innovative immunotherapies aimed at treating diseases linked to chronic inflammation, particularly those associated with aging. Their lead product candidate, HCW9302, has been developed from their proprietary TOBI™ platform, and they have also created a new drug discovery technology known as the TRBC platform. This technology is versatile, allowing the construction of various immunotherapeutic compounds designed to enhance immune responses against diseases like cancer, autoimmune disorders, and other quality-of-life conditions.
The company has already established over 50 molecules using the TRBC platform, focusing on preclinical studies to evaluate their potential. In addition, HCW Biologics has two licensing programs that grant exclusive rights to some proprietary molecules. For more information on their advancements and pipeline, visit their official website.
The summit represents an opportunity for HCW Biologics to showcase its innovative work and engage with potential investors in the rapidly evolving field of biopharmaceuticals.
MWN-AI** Analysis
As HCW Biologics Inc. prepares to participate in the 2025 Maxim Growth Summit, it presents an intriguing opportunity for investors keen on the biotechnology sector, especially in the realm of immunotherapy. The company's focus on chronic inflammation diseases—including age-related and senescence-associated conditions—positions it uniquely in a growing market that increasingly recognizes the importance of addressing these diseases.
HCW Biologics’ proprietary TRBC platform facilitates the development of innovative immunotherapeutics that target cancerous cells and those associated with chronic inflammation. With over 50 drug candidates developed through this technology, potential breakthroughs in cancer treatment and other inflammatory diseases could significantly elevate HCWB’s market presence and valuation—especially as the sector continues evolving towards personalizedmedicine.
Moreover, the upcoming engagement at the Maxim Growth Summit is likely to enhance the visibility of HCW Biologics among institutional investors. One-on-one meetings with Dr. Hing C. Wong, the company’s CEO, offer investors a chance to gain deeper insights into the company’s strategy, pipeline advancements, and broader market conditions in biopharmaceuticals. The Summit's structure, featuring discussions with various sector leaders, will also provide a context for HCWB's competitive positioning and strategic collaborations, which can influence investor sentiment positively.
Investors should consider the stock's potential volatility given its clinical-stage status and reliance on successful trials of its product candidates. However, the emphasis on innovative solutions for chronic inflammatory diseases could attract significant investment, leading to growth in stock value.
In summary, for investors looking for entry points into the biotech sector, HCW Biologics represents a compelling consideration, especially following their anticipated exposure at the Maxim Growth Summit. Monitoring the outcomes of such engagements will be crucial as the company advances its ambitious therapeutic initiatives.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, will be meeting with institutional investors in a one-on-one format, and senior Maxim analysts during the event.
Keynote speakers include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more.
For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit .
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The independent and employee-owned firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group LLC, visit maximgrp.com .
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include the actual success and potency of the Company’s TRBC platform molecules. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.
Company Contact:
Rebecca Byam
Chief Financial Officer
HCW Biologics Inc.
RebeccaByam@HCWBiologics.com
FAQ**
What specific advancements in chronic inflammation treatment does HCW Biologics Inc. (HCWB) anticipate achieving with its TRBC platform at the Maxim Growth Summit 2025?
How does HCW Biologics Inc. (HCWB) plan to enhance investor confidence in its development pipeline and immunotherapeutic technologies showcased at the Maxim Growth Summit?
Can you provide insights into the market potential for HCW Biologics Inc. (HCWB) drugs targeting chronic inflammation and senescence-associated diseases, as discussed in the upcoming 2025 conference?
What key metrics will HCW Biologics Inc. (HCWB) present to institutional investors during the one-on-one meetings at the Maxim Growth Summit to emphasize its growth prospects?
**MWN-AI FAQ is based on asking OpenAI questions about HCW Biologics Inc. (NASDAQ: HCWB).
NASDAQ: HCWB
HCWB Trading
194.2% G/L:
$1.015 Last:
297,600,655 Volume:
$1.11 Open:
